Highlights from Novo Nordisks presentation include (see Figure 1): Analysis of the three components in MACE: Semaglutide 2.4 mg reduced the risk of Non-fatal myocardial infarction by 28% Cardiovascular death by 15% (not statistically significant over the length of the trial) Non-fatal stroke by 7% (not statistically significant over the length of the trial) Analysis of confirmatory secondary endpoints: Semaglutide 2.4 mg reduced the risk of Composite heart failure events, comprising cardiovascular death, urgent heart failure visits and hospitalisations, by 18% Death from any cause by 19% Note: Since the result on cardiovascular death, the first confirmatory secondary endpoint, was not statistically significant over the length of the trial, the remaining secondary confirmatory endpoints were not tested for superiority due to hierarchical testing
But health insurers are reluctant to cover them and that has led to cost coming up very early in these conversations between doctors and their patients
Looking Ahead Tirzepatide is proving to be far more than a weight loss tool
Reduces bloating, gas, acid reflux, and digestive discomfort
10.1096/fj.201801855R 84
About 10 to 30% of people diagnosed with a pulmonary embolism die within 30 days of the diagnosis, so the condition is very dangerous
